Experimental CAR-T therapy targets tough blood cancers in early trial

NCT ID NCT07365059

Not yet recruiting Disease control Sponsor: Qi deng Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new type of immune cell therapy called GPRC5D CAR-T in 18 people with relapsed or treatment-resistant plasma cell disorders, such as multiple myeloma. The therapy involves giving patients a single infusion of their own modified immune cells designed to attack cancer cells. The study aims to check safety, side effects, and whether the treatment shrinks tumors, while also tracking how long the modified cells last in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GPRC5D CAR-T cells (a type of immune cell therapy)
What this could lead to: If it works, this could offer a new treatment option for people with hard-to-treat plasma cell disorders like multiple myeloma.
What could go wrong: This is a very early, small trial (18 people) testing safety first. The therapy may not work or could cause severe side effects, and it is not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTRAMEDULLARY PLASMACYTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AL amyloidosis extramedullary plasmacytoma monoclonal gammopathy plasma cell leukemia plasma cell myeloma plasma cell neoplasm plasmacytoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLASMA CELL DYSCRASIAS

More trials for these conditions

Other studies related to the condition(s) this trial covers.